Trials / Completed
CompletedNCT02786576
Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Patients - a Multi cOuNtry studY in Real Life Setting
Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Patients - a Multi cOuNtry studY in Real Life Setting - HARMONY Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 236 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the effects of adalimumab treatment in moderate to severe Hidradenitis Suppurativa (HS) patients in the real world setting. The objectives of this study are to estimate the effectiveness of adalimumab treatment on disease severity, to estimate the impact of adalimumab treatment on patients' quality of life, psychological effect, work productivity and healthcare resource utilization and to describe treatment practices over the study period.
Conditions
Timeline
- Start date
- 2016-07-05
- Primary completion
- 2019-01-07
- Completion
- 2019-01-07
- First posted
- 2016-06-01
- Last updated
- 2020-01-09
Locations
83 sites across 13 countries: Austria, Belgium, Czechia, Germany, Greece, Hungary, Ireland, Israel, Lebanon, Slovenia, Switzerland, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT02786576. Inclusion in this directory is not an endorsement.